Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Immunology

• Publication date

  2007-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.CLIM.2006.09.001PMID 17046328PMCID PMC2791364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Albumin binding to FcRn: distinct from the FcRn-IgG interaction.

  2006cited by this paper
• Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene.

  2006cited by this paper
• Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces.

  2006cited by this paper
• Perspective-- FcRn transports albumin: relevance to immunology and medicine.

  2006cited by this paper
• Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura.

  2005cited by this paper
• Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1

  2004cited by this paper
• The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs1

  2003cited by this paper
• Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.

  2003cited by this paper
• Lack of correlation between the reduction of serum immunoglobulin concentration and the CTG repeat expansion in patients with type 1 dystrophia [correction of Dystrofia] myotonica.

  2003cited by this paper
• The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan

  2003cited by this paper
• Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.

  2003cited by this paper
• Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.

  2002cited by this paper
• UvA-DARE ( Digital Academic Repository ) Accelerated autoantibody clearance by intravenous immunoglobulin therapy : studies in experimental models to determine the magnitude and time course of the effect

  2001cited by this paper
• Does (CUG)n repeat in DMPK mRNA ‘paint’ chromosome 19 to suppress distant genes to create the diverse phenotype of myotonic dystrophy?:

  2001cited by this paper
• Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy

  2001cited by this paper
• Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).

  2000cited by this paper
• Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells.

  1999cited by this paper
• Protein metabolism in insulin-dependent diabetes mellitus.

  1998cited by this paper
• Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice.

  1998cited by this paper
• Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy.

  1998cited by this paper
• IgG biosynthesis: no "immunoregulatory feedback".

  1997cited by this paper
• Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn

  1996cited by this paper
• The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

  1996cited by this paper
• Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

  1996cited by this paper
• Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice.

  1995cited by this paper
• Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin.

  1990influential reference
• Metabolism of albumin and fibrinogen in type 1 (insulin-dependent) diabetes mellitus.

  1988cited by this paper
• Analbuminemia: Report of a Case and Review of the Literature 1

  1980cited by this paper
• Metabolism of immunoglobulins.

  1969influential reference
• Metabolism of Albumin and γG-Globulin during Albumin Infusions and during Plasmapheresis

  1967cited by this paper
• Molecular biology of human proteins/p=m-/with special reference to plasma proteins

  1967cited by this paper
• Nature and metabolism of extracellular proteins

  1966cited by this paper
• Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism.

  1966influential reference
• Molecular biology of human proteins with special reference to plasma proteins. Vol. 1. Nature and metabolism of extracellular proteins.

  1966cited by this paper
• STUDIES ON THE METABOLISM OF THE SERUM PROTEINS AND LIPIDS IN A PATIENT WITH ANALBUMINEMIA.

  1964cited by this paper
• A THEORETICAL MODEL OF GAMMA-GLOBULIN CATABOLISM.

  1964cited by this paper
• Studies of I-131-albumin catabolism and distribution in normal young male adults.

  1962cited by this paper
• The Kinetics of the Distribution and Breakdown of I131-Albumin in the Rabbit

  1959cited by this paper
• Comparative studies on the half-life of I 131-labeled albumins and nonradioactive human serum albumin in a case of analbuminemia.

  1959cited by this paper
• THE BEHAVIOR OF I131‐LABELED PLASMA PROTEINS IN VIVO

  1957cited by this paper
• Behaviour of 14C- and 131I-labelled plasma proteins in the rat.

  1956cited by this paper
• The distribution of I131 labeled human serum albumin introduced into ascitic fluid: analysis of the kinetics of a three compartment catenary transfer system in man and speculations on possible sites of degradation.

  1954cited by this paper

• Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions

  2026cites this paper
• BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

  2026cites this paper
• Maternal Fine Particulate Matter Exposure Impairs Inguinal White Adipose Tissue Plasticity in Middle-Aged Male Mouse Offspring.

  2026cites this paper
• Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer

  2026cites this paper
• Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress

  2025cites this paper
• Wolf in Sheep’s Clothing: Taming Cancer’s Resistance with Human Serum Albumin?

  2025cites this paper
• Relationships Between Secukinumab Concentrations, Disease Activity, and IL‐17A Levels in Psoriasis: A Cross‐Sectional Observational Study

  2025cites this paper
• Strategies to Enhance Protein Delivery

  2025cites this paper
• Open-label study of efgartigimod in seronegative myasthenia gravis

  2025cites this paper
• Nipocalimab Dose Selection in Generalized Myasthenia Gravis

  2025influential citation
• Ovarian ROS-dependent IgG accumulation precedes lipofuscin deposition and follicular decline: comparative insights from the bitch and mouse models of ovarian aging

  2025cites this paper
• Prophylactic immunoglobulin therapy for pediatric congenital myotonic dystrophy

  2024cites this paper
• Der neonatale Fc-Rezeptor: Biologische Grundlagen und Potenzial der therapeutischen Blockade in der Behandlung immunhämatologischer Erkrankungen

  2024cites this paper
• Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod

  2024cites this paper
• Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies

  2024cites this paper
• IgG is an aging factor that drives adipose tissue fibrosis and metabolic decline.

  2024cites this paper
• Hypogammaglobulinemia and infection risk in myotonic dystrophy type 1

  2024cites this paper
• Kinetics of RPR Decline in Pregnant Persons Treated for Syphilis in Pregnancy and Their Infants

  2024cites this paper
• FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology.

  2024cites this paper
• Deciphering the Role of Maternal Microchimerism in Offspring Autoimmunity: A Narrative Review

  2024cites this paper
• Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease

  2024cites this paper
• Natural IgG protects against early dissemination of vesicular stomatitis virus.

  2024cites this paper
• FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases.

  2024cites this paper
• Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury

  2024cites this paper
• Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade^® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis

  2023cites this paper
• In utero priming of fetal immune activation: Myths and mechanisms.

  2023cites this paper
• No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations

  2023influential citation
• Pharmacokinetics and Pharmacodynamics of Neonatal Fc Receptor (FcRn)-Targeting Therapeutic Proteins: a Systemic Review

  2023cites this paper
• Next generation of multispecific antibody engineering.

  2023cites this paper
• Role of FcγRIII in the nasal cavity of BALB/c mice in the primary amebic meningoencephalitis protection model

  2023cites this paper
• Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease.

  2023cites this paper
• Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor.

  2023cites this paper
• Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01

  2023cites this paper
• Barriers for orally inhaled therapeutic antibodies

  2023cites this paper
• Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats

  2023cites this paper
• Mirikizumab for the treatment of moderate to severe ulcerative colitis.

  2023cites this paper
• T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions

  2023cites this paper
• Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy

  2022cites this paper
• Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

  2022cites this paper
• A Non-radiometric Approach to Determine Tissue Vascular Blood Volume in Biodistribution Studies

  2022cites this paper
• Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

  2022cites this paper
• Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer

  2022cites this paper
• A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity

  2022cites this paper
• Trial designs and endpoints for immune therapies in multiple myeloma

  2022cites this paper
• Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis

  2022cites this paper
• Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.

  2022cites this paper
• Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies

  2022cites this paper
• Does Risk of Hyperhomocysteinemia Depend on Thiol-Disulfide Exchange Reactions of Albumin and Homocysteine?

  2022cites this paper
• Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

  2022cites this paper
• Significance of analyzing circulating plasma cells in multiple myeloma: differences from measuring minimal residual diseases in bone marrow

  2021cites this paper
• Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic

  2021influential citation
• Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains

  2021cites this paper
• Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients

  2021cites this paper
• FcRn antagonists in ITP

  2021cites this paper
• Current Desensitization Strategies in Heart Transplantation

  2021cites this paper
• A Trojan-Horse Strategy by In Situ Piggybacking onto Endogenous Albumin for Tumor-Specific Neutralization of Oncogenic MicroRNA.

  2021cites this paper
• Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques

  2021cites this paper
• The Pathophysiology of Kidney Involvement in Multiple Myeloma and Monoclonal-Related Disorders

  2021cites this paper
• Novel albumin-binding photothermal agent ICG-IBA-RGD for targeted fluorescent imaging and photothermal therapy of cancer

  2021cites this paper
• Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors

  2021cites this paper
• A personalized mass spectrometry-based assay to monitor M-protein in multiple myeloma patients (EasyM)

  2021cites this paper
• Therapeutic antibody development—Remington chapter

  2021cites this paper
• Structural and Biochemical Features of Human Serum Albumin Essential for Eukaryotic Cell Culture

  2021cites this paper
• Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond

  2021cites this paper
• Albumin, as a Therapeutic Protein: Potential Source, Application, Isolation and Puri(cid:976)ication

  2021cites this paper
• A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)

  2021cites this paper
• Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis

  2021cites this paper
• Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review

  2021cites this paper
• The Perioperative Use of Albumin

  2020cites this paper
• Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans

  2020cites this paper
• Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity

  2020cites this paper
• Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations

  2020cites this paper
• Long-term follow-up of antibody titers against measles, mumps, and rubella in recipients of allogenic hematopoietic cell transplantations.

  2020cites this paper
• Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance

  2020cites this paper
• Global immunoglobulin supply: steaming towards the iceberg?

  2020cites this paper
• Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.

  2020cites this paper
• Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma

  2020cites this paper
• Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.

  2020cites this paper
• Novel Therapies for Pemphigus Vulgaris

  2020cites this paper
• Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model.

  2020cites this paper
• Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies

  2020cites this paper
• Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic

  2020cites this paper
• Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients

  2020cites this paper
• Immunoglobulin profile and B‐cell frequencies are altered with changes in the cellular microenvironment independent of the stimulation conditions

  2020cites this paper
• The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis

  2020cites this paper
• Demonstration of fibrinogen-FcRn binding at acidic pH by means of Fluorescence Correlation Spectroscopy.

  2020cites this paper
• A prospective, iterative, adaptive trial of carfilzomib‐based desensitization

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

  2019cites this paper
• A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes

  2019cites this paper
• Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

  2019cites this paper
• Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

  2019cites this paper
• Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans

  2019influential citation
• Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats

  2019cites this paper
• Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease

  2019cites this paper
• Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies

  2019cites this paper
• Improving Pharmacokinetics Reducing In Blood Glucose By Glucagon-Like Peptide-1 Using Albumin-Binding Domain.

  2019cites this paper
• Use of Population Pharmacokinetic Analyses Among FDA‐Approved Biologics

  2019cites this paper
• Immunoglobulin profile and B-cell frequencies are altered with changes in the cellular micro-environment independent of the stimulation conditions

  2019cites this paper
• The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans

  2019cites this paper
• Enhanced serum immunoglobulin G clearance in myotonic dystrophy-associated hypogammaglobulinemia: a case series and review of the literature

  2019cites this paper